109 results match your criteria: "and Baylor University[Affiliation]"

Managing medical and surgical error: an emotional survival guide.

Proc (Bayl Univ Med Cent)

September 2024

Wellness Program, Graduate Medical Education, Baylor University Medical Center, Dallas, Texas, USA.

Medical errors are common and often lead to feelings of self-doubt, helplessness, and guilt. Society thinks of physicians as healers, and physicians who see their role as offering a cure will always feel as if they haven't done enough. This article discusses five steps in the management of medical and surgical error: (1) care for the patient and family, (2) report to appropriate sources, (3) review the incident, (4) manage legal issues, and (5) engage in self-care.

View Article and Find Full Text PDF

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

N Engl J Med

November 2024

From the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London (P.S.); International Breast Cancer Center, Pangaea Oncology, Quirónsalud Group, and Medical Scientia Innovation Research, Barcelona, and IOB Madrid, Institute of Oncology, Hospital Beata María Ana, and the Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid - all in Spain (J.C.); National Cancer Center Singapore, Duke-National University of Singapore Medical School, Singapore (R.D.); University of Texas Southwestern Medical Center (H.M.) and Baylor University Medical Center, Texas Oncology, Sarah Cannon Research Institute (J.O.) - both in Dallas; Yale School of Medicine, Yale Cancer Center, New Haven, CT (L.P.); the Breast Unit, Department of Gynecology with Breast Center, Kliniken Essen-Mitte, Essen (S.K.), Charité-Universitätsmedizin Berlin (S.K.) and the Breast Cancer Center, Helios Klinikum Berlin-Buch (M.U.), Berlin, the Institute of Pathology, Philipps University of Marburg and University Hospital Marburg, Marburg (C.D.), the Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich (N.H.), and University Hospital Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, Erlangen (P.A.F.) - all in Germany; Samsung Medical Center, Sungkyunkwan University School of Medicine (Y.H.P.), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University (S.-A.I.) - both in Seoul, South Korea; Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney (R.H.); the Center of Cancer Medicine, School of Clinical Medicine, University of Hong Kong, Hong Kong (R.H.); Hokkaido University Hospital, Sapporo, Japan (M.T.); Centre Jean-Perrin, Clermont-Ferrand, France (M.-A.M.-R.); the Department of Oncology-Pathology, Karolinska Institutet, and Breast Center, Theme Cancer, Karolinska University Hospital, Stockholm (T.F.); Instituto Português de Oncologia do Porto Francisco Gentil, Porto (M.F.), and the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon (F.C.) - both in Portugal; and the Department of Oncology, Merck, Rahway, NJ (X.Z., V.K., K.T., G.A.).

Background: In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results for overall survival.

Methods: We randomly assigned, in a 2:1 ratio, patients with previously untreated stage II or III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks plus paclitaxel and carboplatin, followed by four cycles of pembrolizumab or placebo plus doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide.

View Article and Find Full Text PDF

Kidney dysfunction is common among liver transplant candidates with decompensated cirrhosis and has a major impact on pre- and post-liver transplant survival. Updated definitions of acute kidney injury and criteria for the diagnosis of hepatorenal syndrome allow for early recognition and intervention, including early initiation of vasoconstrictor therapy for hepatorenal syndrome. The rise of the metabolic syndrome and nonalcoholic fatty liver disease as a cause of cirrhosis has coincided with an increase in intrinsic chronic kidney disease recognized in transplant candidates and recipients.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on outpatient respiratory outcomes in children with severe bronchopulmonary dysplasia (BPD) who require tracheostomy and long-term mechanical ventilation.
  • Researchers analyzed data from 155 patients born between 2016 and 2021 across 12 care centers, using methods like Kaplan-Meier analysis to track key respiratory events and assess timing differences among centers.
  • Findings showed significant variability in outcomes such as age at tracheostomy, hospital discharge, and ventilator liberation across different centers, highlighting the need for further research to understand contributing factors to these differences.
View Article and Find Full Text PDF
Article Synopsis
  • A standardized questionnaire was developed to assess respiratory control in preterm infants and children with bronchopulmonary dysplasia (BPD) during outpatient visits, addressing the lack of valid tools for this purpose.
  • Most caregivers (86.2%) reported feeling their child's symptoms were controlled, regardless of BPD severity or history of pulmonary hypertension, indicating broad perceived stability across the population.
  • The questionnaire proved internally reliable and effectively differentiated between levels of symptom control, correlating with healthcare utilization metrics like emergency visits and hospital admissions, suggesting it may be useful for clinical and research applications.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to determine if daycare attendance increases chronic respiratory issues and healthcare usage in children with bronchopulmonary dysplasia (BPD).
  • It involved 341 preterm infants with BPD, assessing their health outcomes and daycare attendance using structured assessments.
  • Results indicated that those in daycare had more emergency visits, steroid use, and respiratory issues, particularly severe cases attending between 6-12 months, suggesting daycare could be a significant risk factor for respiratory problems in these children.
View Article and Find Full Text PDF
Article Synopsis
  • Preterm infants and children with bronchopulmonary dysplasia (BPD) are at higher risk for respiratory issues and acute care visits, prompting the need to identify risk factors, particularly in those with public insurance like Medicaid.
  • A study with 470 subjects found that children on Medicaid had significantly higher rates of sick visits, emergency department visits, and respiratory admissions compared to those with employer-based insurance.
  • These findings suggest that Medicaid coverage may be linked to increased healthcare utilization and complications, highlighting the necessity for further research on socioeconomic factors and environmental influences on health outcomes in this population.
View Article and Find Full Text PDF

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

N Engl J Med

March 2022

From the Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (C.L.A.), and Baylor University Medical Center, Texas Oncology, US Oncology (J.O.), Dallas - all in Texas; the Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel (S.M.S.); Sarah Cannon Research Institute, Nashville (H.A.B.); the Department of Medical Oncology, National Cancer Centre Singapore, Singapore (Y.-S.Y.); the Department of Medical Oncology, Netherlands Cancer Institute and Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers (L.H.); the Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain (M.C.), and the Department of Medical Oncology, Institut Gustave Roussy, Medical School, Université Paris-Saclay, Villejuif (F.A.) - both in France; the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (E.P.W.); the Department of Gynecology, University of Ulm, Ulm, Germany (W.J.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and the Division of Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy (P.C.); the Edinburgh Cancer Research Centre, Institute of Genomics and Cancer, University of Edinburgh, Edinburgh (D.A.C.); Novartis Pharmaceuticals, East Hanover, NJ (J.P.Z., A.C.); and Novartis Pharma, Basel, Switzerland (T.T., F.L.G., P.S.).

Article Synopsis
  • * After a median follow-up of 6.6 years, results showed that patients receiving ribociclib had a median overall survival of 63.9 months compared to 51.4 months for those on placebo, indicating a significant survival benefit.
  • * The research concluded that first-line treatment with ribociclib plus letrozole significantly improves overall survival without introducing new safety concerns, with an overall survival increase of over 12 months.
View Article and Find Full Text PDF

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

N Engl J Med

February 2022

From Barts Cancer Institute, Queen Mary University of London, London (P.S.); International Breast Cancer Center, Quironsalud Group, and Vall d'Hebron Institute of Oncology, Barcelona (J.C.), and the Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid (J.C.), and Ramon y Cajal University Hospital (M.G.), Madrid; the National Cancer Center Singapore, Duke-National University of Singapore Medical School, Singapore (R.D.); Yale School of Medicine, Yale Cancer Center, New Haven, CT (L.P.); the University of Texas Southwestern Medical Center (H.M.), and Baylor University Medical Center, Texas Oncology, U.S. Oncology Network (J.O.), Dallas, and Texas Oncology, U.S. Oncology Network, Austin (D.P.); the Breast Unit, Kliniken Essen-Mitte, Essen, Charité-Universitätsmedizin Berlin, the Department of Gynecology with Breast Center (S.K.) and the Breast Cancer Center, Helios Klinikum Berlin-Buch (M.U.), Berlin, the Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg (C.D.), the Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich (N.H.), and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, University Hospital Erlangen, Erlangen (P.A.F.) - all in Germany; the Department of Oncology-Pathology, Karolinska Institutet, and Breast Cancer Center, Cancer Theme, Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Solna, Sweden (J.B.); Samsung Medical Center, Sungkyunkwan University School of Medicine (Y.H.P.), Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.A.) - all in Seoul, South Korea; Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney (R.H.), and Royal North Shore Hospital (S.B.-H.) - both in Sydney; Hokkaido Cancer Center, Sapporo, Japan (M.T.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon (F.C.), and Instituto Português de Oncologia do Porto Francisco Gentil, Porto (M.F.) - both in Portugal; Compass Oncology, U.S. Oncology Network, Portland, OR (J.A.); Virginia Oncology Associates, U.S. Oncology Network, Norfolk (M.D.); Centre Jean-Perrin, Clermont-Ferrand, France (M.-A.M.-R.); McGill University, Segal Cancer Centre, Jewish General Hospital, Montreal (J.-F.B.); and Merck, Kenilworth, NJ (Y.D., K.T., G.A., V.K.).

Article Synopsis
  • The study assessed the effect of adding pembrolizumab to neoadjuvant chemotherapy in patients with early triple-negative breast cancer, showing a significant increase in the rates of pathological complete response after surgery compared to the placebo group.
  • A total of 1174 patients were randomly assigned to receive either pembrolizumab with chemotherapy or a placebo, followed by adjuvant therapy post-surgery, with the primary focus on event-free survival and safety.
  • After 39.1 months of median follow-up, the event-free survival rate at 36 months was significantly higher at 84.5% for the pembrolizumab group compared to 76.8% for the placebo group, indicating better outcomes for those
View Article and Find Full Text PDF

¿Qué Está Haciendo Papá? Mexican-Heritage Fathers' Physical Activity Networks After a Father-Focused Health Program.

Fam Community Health

May 2022

Texas A&M University, College Station, Texas (Drs Prochnow, Patterson, and Sharkey) and Baylor University, Waco, Texas (Drs Umstattd Meyer, Talbert, and Meyer).

Physical activity (PA) is a public health priority due to holistic health benefits; however, many adults do not meet PA guidelines. Few studies have examined Mexican-heritage fathers' social networks, specifically with whom they are physically active. This study examines changes in Mexican-heritage fathers' PA networks after participation in a father-focused, family-centered health program.

View Article and Find Full Text PDF

Photodynamic therapy (PDT) can be an effective treatment for actinic keratosis (AK) as well as selected non-melanoma skin cancers (NMSCs), such as Bowen's disease and superficial basal cell carcinoma. PDT has also demonstrated effectiveness in the management of acne vulgaris. Results from controlled clinical trials have shown the safety and efficacy of PDT for these conditions with the use of different photosensitizers and a wide range of light sources.

View Article and Find Full Text PDF

Blunt chest trauma can lead to severe, life-threatening injury to chest organs, including the aorta, heart, lungs, and major airways. We describe a 64-year-old man who had undergone replacement of his aortic valve and ascending aorta 14 years earlier (at age 50) and suddenly developed severe aortic regurgitation after firing his shotgun while hunting. Such an event has not been reported previously.

View Article and Find Full Text PDF

Background: Correct diagnosis of pneumothorax in trauma patients is essential. Under-diagnosis can lead to development of life-threatening tension pneumothorax, but overdiagnosis leads to placement of unnecessary chest tubes with potential related morbidity and pain. It is unclear from previous work if there is a benefit to switching from the phased array (low frequency) probe to the linear (high frequency) probe.

View Article and Find Full Text PDF

Background: Clinical and molecular subcategories of inflammatory bowel disease (IBD) are needed to discover mechanisms of disease and predictors of response and disease relapse. We aimed to develop a study of a prospective adult research cohort with IBD (SPARC IBD) including longitudinal clinical and patient-reported data and biosamples.

Methods: We established a cohort of adults with IBD from a geographically diverse sample of patients across the United States with standardized data and biosample collection methods and sample processing techniques.

View Article and Find Full Text PDF

NCT02959970 Acne vulgaris in patients aged younger than 12 years is increasingly common and primarily noninflammatory (i.e., comedonal).

View Article and Find Full Text PDF
Article Synopsis
  • Bronchopulmonary dysplasia (BPD) is a common respiratory condition among preterm infants, but there's limited outpatient data on their management and outcomes.
  • Seven specialty clinics provided data for a study involving 413 preterm infants, with many having severe BPD; notably, over half of the subjects were nonwhite.
  • The study found that management approaches varied by clinic, but severity of BPD did not influence the use of acute care services, highlighting the role of follow-up care in respiratory outcomes for these children.
View Article and Find Full Text PDF

Purpose: To report the end-of-study results from the Ladder clinical trial of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD).

Design: Multicenter, randomized, active treatment-controlled phase 2 clinical trial.

Participants: Patients diagnosed with nAMD with a documented response to anti-vascular endothelial growth factor treatment who received study treatment (N = 220).

View Article and Find Full Text PDF

A 53-year-old male mountain biker received a total artificial heart and remained in the cardiovascular intensive care unit for 56 days. To reduce functional decline caused by inactivity, he performed a six-session cycle ergometer exercise program in his hospital room. Traditional cardiac responses for exercise prescription were not applicable; therefore, a symptom-limited, monitored progression scheme in conjunction with recommendations for the artificial heart was implemented to modify duration and intensity.

View Article and Find Full Text PDF

Pembrolizumab for Early Triple-Negative Breast Cancer.

N Engl J Med

February 2020

From Barts Cancer Institute, Queen Mary University of London, London (P.S.); International Oncology Bureau Institute of Oncology, Quirón Group, Madrid, and Vall d'Hebron Institute of Oncology, Barcelona (J.C.) - both in Spain; Yale School of Medicine, Yale Cancer Center, New Haven, CT (L.P.); Cedars-Sinai Medical Center, Los Angeles (H.M.); Kliniken Essen-Mitte, Essen (S.K.), the Institute of Pathology, Philipps-University Marburg and University of Marburg, Marburg (C.D.), the Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Ludwig Maximilian University of Munich, University of Munich, Munich (N.H.), University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, Erlangen (P.A.F.), and the Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin (M.U.) - all in Germany; the Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Center, Theme Cancer, Karolinska University Hospital, Solna, Sweden (J.B., T.F.); Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (Y.H.P.); Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney (R.H.); Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan (M.T.); the Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal (F.C.); Merck, Kenilworth, NJ (L.J., V.K., J.Z., G.A.); the National Cancer Center Singapore, Duke-National University of Singapore Medical School, Singapore (R.D.); and Baylor University Medical Center, Texas Oncology and US Oncology, Dallas (J.O.).

Background: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear.

Methods: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide.

View Article and Find Full Text PDF

Utilization Variation In Military Versus Civilian Care: Evidence From TRICARE.

Health Aff (Millwood)

August 2019

Stephen D. Schwab ( ) is an assistant professor of health and business administration at the Army-Baylor Graduate Program, a joint program between the US Army and Baylor University, in San Antonio, Texas.

The Defense Health Agency was established five years ago to integrate and centralize the provision of health care that had been managed separately by the Army, Navy, and Air Force. One favored proposal is to increase the use of private-sector or civilian health care providers. This study compared geographic variation in health care use (a common proxy for efficiency) between patients with a military (direct care) system and those with a civilian (purchased care) system primary care provider-both of which are offered in TRICARE Prime, a health plan that resembles a health maintenance organization.

View Article and Find Full Text PDF

The Use of Ketamine for the Management of Acute Pain in the Emergency Department.

Adv Emerg Nurs J

August 2019

University of South Alabama, Mobile (Dr W. D. Davis); Crook County Medical Services District, Sundance, Wyoming (Dr W. D. Davis); Rocky Mountain University of Health Professions, Provo, Utah (Dr K. A. Davis); and Baylor University Medical Center, Dallas, Texas (Dr Hooper).

Ketamine has been used as an anesthetic agent for over 50 years. At the upper end of the dosing range, it displays dissociative anesthetic and amnestic effects, while at lower doses, it acts as an analgesic and demonstrates opioid-sparing capabilities. Ketamine is unique in its preservation of hemodynamic stability and respiratory function, and is used extensively in the emergency department (ED) for procedural sedation and the facilitation of brief painful procedures.

View Article and Find Full Text PDF

Additive manufacturing has great potential for personalized medicine in osseous fixation surgery, including maxillofacial and orthopedic applications. The purpose of this study was to demonstrate 3D printing methods for the fabrication of patient-specific fixation implants that allow for localized drug delivery. 3D printing was used to fabricate gentamicin (GS) and methotrexate (MTX)-loaded fixation devices, including screws, pins, and bone plates.

View Article and Find Full Text PDF

Objective: Lung cancer is the leading cause of cancer death in people living with HIV (PWH). Surgical resection is a key component of potentially curative treatment regimens for early-stage lung cancers, but its safety is unclear in the setting of HIV. From a national cohort, we assessed potential differences in the risk of major lung cancer surgery complications by HIV status.

View Article and Find Full Text PDF

Objectives: Antibiotic prophylaxis is recommended for prevention of the first episode of spontaneous bacterial peritonitis (SBP; primary prophylaxis 1°) and subsequent episodes (secondary prophylaxis 2°). We aimed to compare outcomes in cirrhotic inpatients on 1° vs 2° SBP prophylaxis.

Methods: Data from North American Consortium for the Study of End-Stage Liver Disease were evaluated for cirrhosis details, reasons for admission/medications, inpatient course recorded, and outcomes over 90 days.

View Article and Find Full Text PDF